TL;DR: The GLP-1 receptor agonist landscape in 2026 spans four distinct compounds: semaglutide (selective GLP-1 RA, MW 4113.58 Da, injectable and oral), tirzepatide (dual GLP-1/GIP agonist, MW 4813.45 Da), retatrutide (triple GLP-1/GIP/glucagon agonist, MW ~4500 Da, Phase 3), and orforglipron (non-peptide oral GLP-1 agonist, MW 541.65 Da, FDA-approved April 2026)
Taurine levels in the cultured hepatocytes isolated from Cdo1 / mice ranged from 4.6 to 6.2 % of the corresponding wild-type levels (this study), whereas taurine levels in the liver of Cdo1 / mice fed on taurine-free diets were found to be consistently less than 5 % of the wild-type levels (previously published study)
One approach to addressing and managing irAEs is to differentiate this conventional autoimmunity from immunotherapy-induced autoimmunity
"Peptides and Ageing." Neuroendocrinology Letters
Also, we have established a process where session speakers can do an internal mock presentation prior to the actual AMCP meeting
PAD Hiatt 2001 American Journal of Medicine RCTn=155 Propionyl-L-carnitinePLC 2 g 12 54%vs
